Clinical Trial Detail

NCT ID NCT02485990
Title Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

ovarian carcinoma

peritoneal carcinoma

fallopian tube carcinoma

Therapies

Olaparib

Tremelimumab

Age Groups: adult

No variant requirements are available.